Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its target price increased by BMO Capital Markets from $14.00 to $15.00 in a research report issued to clients and investors on Friday, September 15th. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target points to a potential downside of 13.64% from the company’s current price.
A number of other equities research analysts have also recently weighed in on HALO. Piper Jaffray Companies set a $20.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. Barclays PLC reissued an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Friday, August 25th. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Jefferies Group LLC reissued an “underperform” rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $16.63.
Halozyme Therapeutics (HALO) traded down 0.17% during midday trading on Friday, reaching $17.37. The company had a trading volume of 908,426 shares. The company’s market capitalization is $2.33 billion. The firm has a 50-day moving average price of $13.01 and a 200-day moving average price of $13.28. Halozyme Therapeutics has a 52 week low of $8.18 and a 52 week high of $17.62.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $31.76 million. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm earned ($0.21) earnings per share. Analysts expect that Halozyme Therapeutics will post ($0.22) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given New $15.00 Price Target at BMO Capital Markets” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/02/halozyme-therapeutics-inc-halo-pt-raised-to-15-00.html.
A number of hedge funds have recently modified their holdings of HALO. Ameritas Investment Partners Inc. purchased a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $122,000. Teacher Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics in the second quarter worth $129,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $131,000. Prudential Financial Inc. lifted its position in shares of Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 940 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $171,000. 85.06% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.